TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04627428: Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

Sponsor: Luxa Biotechnology, LLC · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$620,840

Rescue Site Savings

+$423,300

Unlock Full NCT04627428 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04627428 Rescue Dossier →